ArticleDiscover oncology2026
SHH drives gastric cancer-associated fibroblast activation via ACLY-dependent acetyl-CoA metabolism and histone acetylation.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Gastric cancer, the fifth most common malignancy worldwide, is characterized by poor prognosis due to its aggressive progression and therapeutic resistance, largely driven by the tumor microenvironment (TME). Cancer-associated fibroblasts (CAFs), as the predominant stromal component, contribute to tumor progression, metastasis, and chemoresistance through metabolic reprogramming and epigenetic modifications. Here, we investigated the role of Sonic Hedgehog (SHH) signaling in regulating ATP-citrate lyase (ACLY)-dependent acetyl-CoA metabolism and histone acetylation during gastric CAF activation. Primary CAFs exhibited elevated fibroblast activation markers (FAP1, α-SMA) compared to normal gastric fibroblasts (NFs). SHH stimulation or co-culture with gastric cancer cells robustly upregulated ACLY transcription and protein expression in NFs, synergistically enhancing acetyl-CoA production. Genetic ACLY knockdown or pharmacologic inhibition attenuated SHH-induced CAF activation markers (α-SMA, FAP1, FSP1) and reduced intracellular acetyl-CoA levels by > 50%, concomitant with diminished global histone H3 acetylation. Chromatin immunoprecipitation revealed SHH-driven enrichment of H3 acetylation at promoters of CAF marker genes, which was reversed by ACLY silencing or histone acetyltransferase inhibition. Moreover, tumor cell-conditioned medium recapitulated these metabolic-epigenetic changes in NFs. Our findings establish SHH/ACLY/acetyl-CoA as a novel axis linking stromal metabolism to epigenetic reprogramming in gastric CAFs, wherein ACLY-generated acetyl-CoA fuels histone acetylation to activate pro-tumorigenic transcriptional programs. This study unveils a therapeutically targetable mechanism underlying TME remodeling, positioning ACLY as a stromal metabolic checkpoint in gastric cancer progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.